The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Saved in:
| Title: | The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC. |
|---|---|
| Authors: | Patil T; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Staley A; University of Colorado Cancer Center Biostatistics Core, University of Colorado School of Medicine, Aurora, Colorado., Nie Y; Department of Medical Oncology, Yale School of Medicine, Yale University, New Haven, Connecticut., Sakamoto M; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Stalker M; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Jurica JM; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Koehler K; Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Cass A; Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Kuykendall H; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Schmitt E; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Filar E; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Reventaite E; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Davies KD; Department of Pathology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Nijmeh H; Department of Pathology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Haag M; Department of Pathology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Yoder BA; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Bunn PA; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Schenk EL; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Aisner DL; Department of Pathology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado., Iams WT; Division of Medical Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee., Marmarelis ME; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Camidge DR; Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado. |
| Source: | JTO clinical and research reports [JTO Clin Res Rep] 2024 Jan 18; Vol. 5 (2), pp. 100637. Date of Electronic Publication: 2024 Jan 18 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
